Abbvie (ABBV) news
Recent news
Cytomx TherA gets FDA fast track designation for Varseta-M
CytomX Therapeutics has announced plans for an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational therapy Varsetatug masetecan (Varseta-M) for the treatment of late-line metastatic colorectal cancer (mCRC). The company aims to align with the FDA on the…
AInvest Wire · 1d agoHaisco Pharmaceutical H1 net profit up 427.0% y/y
Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) reported a net profit of RMB 790 million to RMB 870 million for the first half of 2026, representing a year-on-year increase of 513.25% to 575.35% . This significant growth was driven by the continued strong performance of its innovative drug sales…
AInvest Wire · 2d agoNexera Pharma Co., - Milestone payment expected to be recognized as revenue in Q3 FY2026
Nxera Pharma (TSE: 4565) reported continued progress in its partnered programs and commercial activities during the second quarter of FY2026, with several key developments expected to contribute to revenue in the coming quarters. The company highlighted that it has achieved multiple milestones…
AInvest Wire · 2d agoGubra reports achievement of milestone from AbbVie
AbbVie and Gubra have announced that a key milestone has been achieved in the development of GUB014295, a long-acting amylin analog for the treatment of obesity. Under the terms of their 2025 license agreement, Gubra is now eligible to receive corresponding payments as part of the $1.875 billion in…
AInvest Wire · 2d agoGubra 2Q revenue DKK50.6M
Gubra reported revenue of DKK 50.6 million for the second quarter of 2025, representing a 12% increase compared to DKK 49.0 million in the same period of the previous year. This growth was part of a broader performance across the company’s CRO segment, which saw revenue for the first half of 2025…
AInvest Wire · Aug 20, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.